Ricardo Roman
Internal Medicine · Eagle Rock, CANPI 1144327032
Payments from drug & device makers
Across 472 payments — averaging $74.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$6K
- AstraZeneca$5K
- Amgen$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- GSK$2K
- Novo Nordisk$2K
- plus $18K from 54 others
What the payments were for
- Travel & lodging$190%
- Food & beverage$35,161100%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,197 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 71 | $126,379 |
| JardianceEmpagliflozin | 117 | $98,483 |
| OzempicSemaglutide | 71 | $69,399 |
| EliquisApixaban | 22 | $23,101 |
| FarxigaDapagliflozin Propanediol | 26 | $21,617 |
| Diclofenac Sodium | 14 | $14,748 |
| Metformin Er GastricMetformin Hcl | 13 | $13,158 |
| JanuviaSitagliptin Phosphate | 16 | $12,291 |
| EntrestoSacubitril/Valsartan | 13 | $11,719 |
| Repatha SureclickEvolocumab | 11 | $11,275 |
| GemtesaVibegron | 17 | $8,539 |
| LipitorAtorvastatin Calcium | 11 | $5,727 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 47 | $5,335 |
| AtacandCandesartan Cilexetil | 12 | $3,564 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $3,147 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $1,520 | $195,777142 claims |
| Boehringer IngelheimJardiance | $866 | $98,483117 claims |
| PfizerEliquis, Lipitor | $185 | $28,82833 claims |
| AstraZenecaFarxiga, Atacand, Symbicort | $4,692 | $28,32852 claims |
| MerckJanuvia | $112 | $12,29116 claims |
| NovartisEntresto | $364 | $11,71913 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $163 | $8,53917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Eagle Rock
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.